New drug applications approved by US FDA as of 01 - 15 November 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The triplet regimen of encorafenib, binimetinib and cetuximab provides significant and clinically relevant benefits in overall survival (OS) and objective response rate (ORR) in patients with BRAF V600E-mutated metastatic colorectal cancer (mCRC) who experience disease progression after one or two previous regimens, according to results of an interim analysis of the BEACON CRC trial.
A systematic review and meta-analysis evaluating two percutaneous ablation techniques – microwave ablation (MWA) and radiofrequency ablation (RFA) – showed that the former fared better than the latter in reducing local tumour progression (LTP) rates in individuals with hepatocellular carcinoma (HCC) and/or liver metastases.
The addition of pertuzumab to a trastuzumab-docetaxel regimen in the neoadjuvant setting improved total pathological complete response (tpCR) rates in Asian women with early or locally advanced ERBB2-positive breast cancer, according to the phase III PEONY trial from China.
Quality of life (QoL) in breast cancer patients worsens 2 years following diagnosis with different courses by treatment received, a study has found. Specifically, endocrine therapy exerts a major detrimental impact on QoL as opposed to chemotherapy having a transient negative effect in postmenopausal patients.